Cognitive impairment (CI) is a key feature of late life depression (LLD), but the contribution of underlying neurodegenerative pathology remains unclear.
Objective:
To evaluate cognitive dysfunction in LLD relative to a sample of nondepressed (ND) older adults with matched levels of memory impairment and amyloid-β (Aβ) burden.
Methods:
Participants included 120 LLD and 240 ND older adults matched on age, education, sex, Mini-Mental State Exam, mild cognitive impairment diagnosis, and PET Aβ burden.
Results:
LLD showed higher rates of impairment relative to ND with 54.6% of the LLD sample demonstrating impairment in at least one cognitive domain compared to 42.9% of controls (H = 7.13, p = 0.008). LLD had poorer performance and higher rates of impairment on Rey Auditory Verbal Learning Test learning and memory compared to controls. In the overall sample, Aβ positivity was associated with worse performance on Logical Memory I (p = 0.044), Logical Memory II (p = 0.011), and Trail Making Test –B (p = 0.032), and APOEɛ4 genotype was associated with worse performance on Logical Memory I (p = 0.022); these relationships did not differ between LLD and ND.
Conclusion:
LLD showed higher rates of CI driven by focal deficits in verbal learning and memory. Alzheimer’s disease (AD) biomarkers were associated with worse performance on timed set-shifting and story learning and memory, and these relationships were not impacted by depression status. These findings suggest that AD may account for a portion of previously reported multi-domain CI in LLD and highlight the potential for AD to confound studies of cognition in LLD.
BlazerDG (2003) Depression in late life: Review and commentary. J Gerontol A Biol Sci Med Sci58, M249–M265.
2.
SteffensDC, FisherGG, LangaKM, PotterGG, PlassmanBL (2009) Prevalence of depression among older Americans: The Aging, Demographics and Memory Study. Int Psychogeriatr21, 879–888.
3.
GabryelewiczT, StyczynskaM, LuczywekE, BarczakA, PfefferA, AndrosiukW, Chodakowska-ZebrowskaM, WasiakB, PeplonskaB, BarcikowskaM (2007) The rate of conversion of mild cognitive impairment to dementia: Predictive role of depression. Int J Geriatr Psychiatry22, 563–567.
4.
ByersAL, YaffeK (2011) Depression and risk of developing dementia. Nat Rev Neurol7, 323–331.
5.
BeekmanAT, PenninxBW, DeegDJ, de BeursE, GeerlingSW, van TilburgW (2002) The impact of depression on the well-being, disability and use of services in older adults: A longitudinal perspective. Acta Psychiatr Scand105, 20–27.
6.
BruceML, Ten HaveTR, ReynoldsCF3rd, KatzII, SchulbergHC, MulsantBH, BrownGK, McAvayGJ, PearsonJL, AlexopoulosGS (2004) Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: A randomized controlled trial. JAMA291, 1081–1091.
7.
AlexopoulosGS (2005) Depression in the elderly. Lancet365, 1961–1970.
8.
AlexopoulosGS, MeyersBS, YoungRC, KalayamB, KakumaT, GabrielleM, SireyJA, HullJ (2000) Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry57, 285–290.
9.
KiossesDN, KlimstraS, MurphyC, AlexopoulosGS (2001) Executive dysfunction and disability in elderly patients with major depression. Am J Geriatr Psychiatry9, 269–274.
10.
MackinRS, DelucchiKL, BennettRW, AreánPA (2011) The effect of cognitive impairment on mental healthcare costs for individuals with severe psychiatric illness. Am J Geriatr Psychiatry19, 176–184.
11.
KoenigAM, BhallaRK, ButtersMA (2014) Cognitive functioning and late-life depression. J Int Neuropsychol Soc20, 461–467.
12.
ButtersMA, WhyteEM, NebesRD, BegleyAE, DewMA, MulsantBH, ZmudaMD, BhallaR, MeltzerCC, PollockBG, ReynoldsCF3rd, BeckerJT (2004) The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry61, 587–595.
13.
ArveS, TilvisRS, LehtonenA, ValvanneJ, SairanenS (1999) Coexistence of lowered mood and cognitive impairment of elderly people in five birth cohorts. Aging Clin Exp Res11, 90–95.
14.
BhallaRK, ButtersMA, MulsantBH, BegleyAE, ZmudaMD, SchoderbekB, PollockBG, ReynoldsCF, BeckerJT (2006) Persistence of neuropsychologic deficits in the remitted state of late-life depression. Am J Geriatr Psychiatry14, 419–427.
15.
KöhlerS, ThomasAJ, BarnettNA, O’BrienJT (2010) The pattern and course of cognitive impairment in late-life depression. Psychol Med40, 591–602.
16.
BooneKB, LesserIM, MillerBL, WohlM, BermanN, LeeA, PalmerB, BackC (1995) Cognitive functioning in older depressed outpatients: Relationship of presence and severity of depression to neuropsychological test scores. Neuropsychology9, 390–398.
17.
LesserIM, BooneKB, MehringerCM, WohlMA, MillerBL, BermanNG (1996) Cognition and white matter hyperintensities in older depressed patients. Am J Psychiatry153, 1280–1287.
18.
BhallaRK, ButtersMA, BeckerJT, HouckPR, SnitzBE, LopezOL, AizensteinHJ, RainaKD, DeKoskyST, ReynoldsCF3rd (2009) Patterns of mild cognitive impairment after treatment of depression in the elderly. Am J Geriatr Psychiatry17, 308–316.
19.
HeatonRK, AvitableN, GrantI, MatthewsCG (1999) Further crossvalidation of regression-based neuropsychological norms with an update for the Boston Naming Test. J Clin Exp Neuropsychol21, 572–582.
20.
ButtersMA, BeckerJT, NebesRD, ZmudaMD, MulsantBH, PollockBG, ReynoldsCF (2000) Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry157, 1949–1954.
21.
LeeJS, PotterGG, WagnerHR, Welsh-BohmerKA, SteffensDC (2007) Persistent mild cognitive impairment in geriatric depression. Int Psychogeriatr19, 125–135.
22.
ReynoldsCF3rd, ButtersMA, LopezO, PollockBG, DewMA, MulsantBH, LenzeEJ, HolmM, RogersJC, MazumdarS, HouckPR, BegleyA, AndersonS, KarpJF, MillerMD, WhyteEM, StackJ, GildengersA, SzantoK, BensasiS, KauferDI, KambohMI, DeKoskyST (2011) Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry68, 51–60.
ValkanovaV, EbmeierKP, AllanCL (2013) CRP, IL-6 and depression: A systematic review and meta-analysis of longitudinal studies. J Affect Disord150, 736–744.
25.
ReasET, LaughlinGA, BergstromJ, Kritz-SilversteinD, Barrett-ConnorE, McEvoyLK (2019) Effects of APOE on cognitive aging in community-dwelling older adults. Neuropsychology33, 406–416.
26.
SmallBJ, RosnickCB, FratiglioniL, BäckmanL (2004) Apolipoprotein E and cognitive performance: A meta-analysis. Psychol Aging19, 592–600.
27.
MattssonN, GrootC, JansenWJ, LandauSM, VillemagneVL, EngelborghsS, MintunMM, LleoA, MolinuevoJL, JagustWJ, FrisoniGB, IvanoiuA, ChételatG, Resende de OliveiraC, RodrigueKM, KornhuberJ, WallinA, Klimkowicz-MrowiecA, KandimallaR, PoppJ, AaltenPP, AarslandD, AlcoleaD, AlmdahlIS, BaldeirasI, van BuchemMA, CavedoE, ChenK, CohenAD, FörsterS, ForteaJ, FrederiksenKS, Freund-LeviY, GillKD, GkatzimaO, GrimmerT, HampelH, HerukkaS-K, JohannsenP, van LaereK, de LeonMJ, MaierW, MarcussonJ, MeulenbroekO, MøllergårdHM, MorrisJC, MroczkoB, NordlundA, PrabhakarS, PetersO, RamiL, Rodríguez-RodríguezE, RoeCM, RütherE, SantanaI, SchröderJ, SeoSW, SoininenH, SpiruL, StomrudE, StruyfsH, TeunissenCE, VerheyFRJ, VosSJB, van Waalwijk van DoornLJC, WaldemarG, WallinÅK, WiltfangJ, VandenbergheR, BrooksDJ, FladbyT, RoweCC, DrzezgaA, VerbeekMM, SarazinM, WolkDA, FleisherAS, KlunkWE, NaDL, Sánchez-JuanP, LeeDY, NordbergA, TsolakiM, CamusV, RinneJO, FaganAM, ZetterbergH, BlennowK, RabinoviciGD, HanssonO, van BerckelBNM, van der FlierWM, ScheltensP, VisserPJ, OssenkoppeleR (2018) Prevalence of the apolipoprotein E ɛ4 allele in amyloid β positive subjects across the spectrum of Alzheimer’s disease. Alzheimers Dement14, 913–924.
28.
MichaelsonDM (2014) APOE epsilon4: The most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimers Dement10, 861–868.
29.
PetersenRC, WisteHJ, WeigandSD, RoccaWA, RobertsRO, MielkeMM, LoweVJ, KnopmanDS, PankratzVS, MachuldaMM, GedaYE, JackCRJr (2016) Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol73, 85–92.
30.
KumarA, KepeV, BarrioJR, SiddarthP, ManoukianV, Elderkin-ThompsonV, SmallGW (2011) Protein binding in patients with late-life depression. Arch Gen Psychiatry68, 1143–1150.
31.
LiP, HsiaoI-T, LiuC-Y, ChenC-H, HuangS-Y, YenT-C, WuK-Y, LinK-J (2017) Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: A pilot study. EJNMMI Res7, 24–24.
32.
ButtersMA, KlunkWE, MathisCA, PriceJC, ZiolkoSK, HogeJA, TsopelasND, LoprestiBJ, ReynoldsCF3rd, DeKoskyST, MeltzerCC (2008) Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord22, 261–268.
33.
HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23, 56.
34.
FirstMB, SpitzerRL, GibbonM, WilliamsJB (1997) User’s guide for the Structured clinical interview for DSM-IV axis I disorders SCID-I: Clinician version, American Psychiatric Pub.
PetersenRC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med256, 183–194.
37.
GuilmetteTJ, SweetJJ, HebbenN, KoltaiD, MahoneEM, SpieglerBJ, StuckyK, WesterveldM, Conference Participants (2020) American Academy of Clinical Neuropsychology consensus conference statement on uniform labeling of performance test scores. Clin Neuropsychol34, 437–453.
38.
RosenWG, MohsRC, DavisKL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry141, 1356–1364.
39.
WechslerD (1997) Wechsler memory scale - Third Edition (WMS-III), Psychological Corporation, San Antonio.
40.
ReyA (1964) Presses Universitaries De France, Oxford, England. L’examen clinique en psychologie. [The clinical examination in psychology.].
41.
KaplanE, GoodglassH, WeintraubS (1983) The Boston Naming Test. Lea & Febiger. Philadelphia, PA.
42.
ButtersN, GranholmE, SalmonDP, GrantI, WolfeJ (1987) Episodic and semantic memory: A comparison of amnesic and demented patients. J Clin Exp Neuropsychol9, 479–497.
43.
ReitanRM (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills8, 271–276.
BornC, AmannBL, GrunzeH, PostRM, ScharerL (2014) Saving time and money: A validation of the self ratings on the prospective NIMH Life-Chart Method (NIMH-LCM). BMC Psychiatry14, 130.
LandauSM, LuM, JoshiAD, PontecorvoM, MintunMA, TrojanowskiJQ, ShawLM, JagustWJ, Alzheimer’s Disease Neuroimaging Initiative (2013) Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol74, 826–836.
48.
ClarkCM, PontecorvoMJ, BeachTG, BedellBJ, ColemanRE, DoraiswamyPM, FleisherAS, ReimanEM, SabbaghMN, SadowskyCH, SchneiderJA, AroraA, CarpenterAP, FlitterML, JoshiAD, KrautkramerMJ, LuM, MintunMA, SkovronskyDM (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study. Lancet Neurol11, 669–678.
49.
SaykinAJ, ShenL, YaoX, KimS, NhoK, RisacherSL, RamananVK, ForoudTM, FaberKM, SarwarN, MunsieLM, HuX, SoaresHD, PotkinSG, ThompsonPM, KauweJSK, Kaddurah-DaoukR, GreenRC, TogaAW, WeinerMW (2015) Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimers Dement11, 792–814.
50.
HolmS (1979) A simple sequentially rejective multiple test procedure. Scand Stat Theory Appl6, 65–70.
51.
R Core Team (2017) R Foundation for Statistical Computing, Vienna, Austria.
52.
ShelineYI, BarchDM, GarciaK, GersingK, PieperC, Welsh-BohmerK, SteffensDC, DoraiswamyPM (2006) Cognitive function in late life depression: Relationships to depression severity, cerebrovascular risk factors and processing speed. Biol Psychiatry60, 58–65.
53.
LockwoodKA, AlexopoulosGS, van GorpWG (2002) Executive dysfunction in geriatric depression. Am J Psychiatry159, 1119–1126.
54.
RoweCC, EllisKA, RimajovaM, BourgeatP, PikeKE, JonesG, FrippJ, Tochon-DanguyH, MorandeauL, O’KeefeG (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging31, 1275–1283.
